PADに対する新たなアフェレシス療法の可能性(<特集>動脈硬化とアフェレシス)

概要

論文の詳細を見る
Low-density lipoprotein (LDL) apheresis has been established as a valuable treatment for peripheral arterial disease (PAD). The effectiveness for PAD patients has been reported, especially on dialysis, even though hypercholesterolemia does not exist. Thus, it is speculated that unidentified mechanisms, other than LDL cholesterol removal, may result in these conditions during LDL apheresis. Therefore, it may be reasonable to speculate the presence of other targets for apheresis. Rheopheresis and cytapheresis may be the new approaches for PAD. Removal of fibrinogen by rheopheresis is being attempted to improve blood rheology and microcirculation. Chronic inflammation is well known to be an important factor for atherosclerosis. Leukocytapheresis (LCAP) is one of the procedures to suppress inflammation through the control of the cytokine/chemokine system and modulation of regulatory T cells (Treg), suggesting the possible treatment for atherosclerosis. Further investigation, based on molecular biological evidence, is needed in future.
2013-02-28